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Abstract 
Immunosuppression in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is 
complicated by increasing risk of infections including opportunistic infections like, Pneumocystis jirovecii 
pneumonia (PJP). Available evidence on risk factors and indications for prophylaxis in AAV is derived from 
PJP occurring early in the course of AAV. In this retrospective study, we characterized the profile of PJP in 
patients with AAV. PJP cases were identified retrospectively based on positive polymerase chain reaction test 
from electronic record followed by confirmation from medical records over 10 year period. AAV patients 
without PJP over the same period were used as control group. Sixteen PJP+AAV+ were identified, in fourteen 
of them we were able to confirm they received PJP prophylaxis during induction therapy, While in two cases 
data were missing.  The onset of the infection was after 6 months from AAV diagnosis in 80% of cases. 
Escalations in immunosuppression prior to PJP were observed in six cases within 3 months prior to PJP onset. 
Overall mortality was 12.5%. By univariate analysis, renal involvement at AAV diagnosis was associated with 
PJP.  These results indicate that PJP is not limited to the first six months following AAV diagnosis. Late onset 
infection can occur in context of augmented immunotherapy, particularly with concurrent lymphopenia. Other 
risk factors that can independently predict late onset PJP remains to be identified. 
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 Introduction 
Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) are chronic inflammatory conditions 
of unclear aetiology. They comprise three categories: granulomatosis with polyangiitis (GPA), microscopic 
polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) [1]. Despite advances in both 
induction and maintenance treatment with less toxic regimes, infections continue to contribute heavily to 
morbidity and mortality[2, 3]. The majority of these infections tend to be pulmonary in origin and the severity of 
the infection have been linked to mortality in a number of previous studies [2–5].  Pneumocystis jirovecii 
pneumonia (PJP) is an opportunistic fungal infection that had been reported with the use of various induction 
therapies in AAV [6–8]. Interference with cell-mediated immunity, particularly with low CD4 counts predispose 
to the infection[9]. Optimal duration for prophylaxis against PJP remains uncertain, in our group median time 
from disease onset to PJP diagnosis is 8 months [10–12]. An established risk factor for PJP in GPA (and other 
connective tissue diseases) is the presence of lymphopenia[8, 13]. We performed a retrospective analysis on all 
PJP+ cases with AAV in our tertiary referral centre using unbiased case identification over a 10 years period. 
The primary aim was to characterize the time between AAV diagnosis and onset of PJP and examining 
associated risk factors.  
Methods 
Microbiology department database in Aberdeen Royal Infirmary was used to identify all patient with positive 
PJP result by polymerase chain reaction (PCR) between 31st of March 2006 until 1st of August 2016. The cases 
were then divided based on their underlying diagnosis to onco-haematological malignancies, HIV, renal 
transplants, interstitial lung disease (unrelated to systemic vasculitis), and rheumatological diseases. The latter 
group was then divided into rheumatoid arthritis, AAV, and other vasculitides. Data on the PJP patients were 
collected from case notes and electronic records. These included: age, sex, time of AAV diagnosis, AAV type, 
ANCA type, time of PJP, diagnosis of PJP (clinical presentation and radiologic abnormalities) and type of 
biological specimen used in PCR (induced sputum or bronchoalveolar lavage, BAL). Laboratory data included: 
renal function (at time of AAV presentation, prior to PJP diagnosis, during hospitalization, and after discharge 
from hospital) and lymphocyte counts (at the end of induction therapy and within 30 days before PJP infection). 
Lymphocyte count of <0.3 was considered as severe lymphopenia[13]. In addition, data was collected on 
immunosuppressive drugs used during induction and maintenance phases including corticosteroid dose at the 
time of PJP diagnosis. In our centre, oral Cyclophosphamide, CyC, (1.5mg/kg) with oral steroids tapering 
regime is the first line of treatment for organ or life-threatening AAV. Rituximab is used when 
Cyclophosphamide is contraindicated or not tolerated. Adjunctive plasma exchange is used in the presence of 
pulmonary haemorrhage, serum creatinine of >500 µmol/, or rapidly declining renal function. Mycophenolate 
mofetil (MMF) or Methotrexate (MTX) are used for non-organ threatening AAV. Low dose steroids with 
Azathioprine (AZA), Rituximab, MMF or MTX are used for maintenance remission. Major disease relapse is 
treated with Rituximab (or oral Cyclophosphamide if no previous exposure) and steroid dose escalation. Minor 
relapse is treated with either modest increase in steroid therapy or switching Azathioprine to MMF or MTX. The 
clinical and laboratory profile of PJP cases were compared to control group of AAV cases without PJP (n=141) 
to examine potential risk factors for developing PJP. Major and minor relapse definition followed criteria 
previously reported in MYCYC trial[14]. 
Statistical analysis 
Descriptive statistics included the number (n), percentage (%) or median with interquartile range (IQR). 
Categorical variables were compared using Chi square test. Continuous variable were compared using Mann-
Whitney U test. A p value of <0.05 was considered significant. Binary logistic regression was used to test 
potential predictors. Two tailed p value of less than 0.05 was considered to be significant. All statistical analysis 
was done using SPSS version 24.  
Results  
This study included 16 PJP+AAV+ patients out of total of 142 PJP cases over 10 years period. This group 
comprised 11% of the total PJP population. Other clinical backgrounds with PJP included; oncohaematology 
48%, HIV 18%, renal transplants 9%, rheumatoid arthritis 7%, interstitial lung disease 4%, and 
glomerulonephritis 2%. All PJP+AAV+ cases had clinical presentation and radiologic evidence of PJP. Table 1 
shows summary of characteristics of these patients. The median age at PJP diagnosis was 66.5 years. The 
majority of AAV patients had GPA (75%). Almost all (15 out of 16) PJP+AAV+ cases received oral CyC for 
induction therapy. Data on PJP prophylaxis were available in 14 cases, all of whom received Co-trimoxazole 
(CTX) prophylaxis during induction treatment. AZA was the predominant agent used during maintenance phase. 
The median time from AAV diagnosis to PJP was 8 months (25th -75th percentile 7-127.5months). The median 
Prednisolone dose at the time when PJP diagnosed was 10mg. Four patients were receiving more than 20 mg of 
Prednisolone at the time of PJP diagnosis.  Increments in immunotherapy were observed in 6 cases within 3 
months from diagnosis of PJP infection. Further details about disease relapses and augmentation on 
immunotherapy are available in Table 2. 
Lymphopenia was present in all cases with a median lymphocyte count of 0.35 cells/L.CTX was used to treat 
PJP in 14 patients. Two patients were intolerant to CTX and were treated with combination of Clindamycin & 
Primaquine. Two patients required invasive ventilation and both did not survive accounting for 12.5% mortality. 
Comparison between PJP+ and control  (n=141) groups revealed no differences in age or sex at the time of 
vasculitis diagnosis. Comparison of maintenance treatment between both groups was not possible due to lack of 
good quality data for control group, however, available data for 129 control cases (out of 141 cases) revealed 
that Azathioprine was used as maintenance treatment in 88 cases (68%), MMF in 24 cases (19%), Methotrexate 
in 6 cases (4.7%) while Rituximab was used in 8 cases  (6%). 
Higher frequency of renal involvement, lymphopenia, and use of oral CyC were observed in the PJP+AAV+ 
compared to the PJP-AAV+ controls (Table 3). Univariate binary logistic regression of renal involvement at the 
time of diagnosis of AAV, lymphopenia at the end of induction and oral CyC use showed that absence of renal 
involvement was associated with less risk of PJP (OR 0.18, 95% CI 0.04-0.84, p=0.03). None of these 
covariates were predictors of PJP in multivariate analysis. 
 
  
 
 
Discussion 
 In this study, the majority of PJP infections occurred beyond six months from AAV diagnosis, often preceded 
by augmenting immunotherapy. Lymphopenia was observed in all patients that developed PJP prior to the onset 
of infection.  Although CTX prophylaxis was almost uniformly used during induction treatment, re-introducing 
CTX was not evident during escalation of immunosuppression.  Traditional risk factors such as renal 
involvement at the time of AAV diagnosis, use of oral CyC, and lymphopenia at the end of induction therapy 
were not predictors of acquiring PJP in this study. 
Previous studies on PJP in AAV were primarily retrospective observational studies focusing on GPA [10, 11, 
13, 15, 16]. The onset of PJP in most of these studies was closely related to the induction phase of therapy. The 
European League Against Rheumatism (EULAR) guidelines reflected this observation and encouraged the use 
of CTX during treatment with CyC[17]. In our study the majority of cases happened beyond the period of 
induction therapy with median time between AAV diagnosis and PJP of 8 months. This observation suggests 
that extended prophylaxis might be of value, particularly in the presence of persistent lymphopenia. In our 
series, more than a third of PJP infections occurred in context of escalation of immunotherapy. Only one case 
had received CTX prophylaxis along with treatment escalation, this also can be interpreted, as CTX prophylaxis 
is effective. 
The use of corticosteroids is suspected to be a risk factor for PJP [8]. The cut off value for corticosteroid dose is 
not entirely clear and can be between 15-40 mg Prednisone equivalent per day[18–20]. In our study, 75% of the 
cases were on less than 20 mg Prednisolone per day prior to occurrence of PJP. Lymphopenia has been 
consistently reported as a useful predictor of PJP. The cut off value for lymphopenia <600/mm3 at 3 months of 
treatment[13] or a lymphocyte count off <500 cells/µl at two weeks after starting corticosteroid therapy (>30 
mg/day) [19]. Other traditional PJP risk factors in AAV such as renal involvement and CyC usage were not 
predictors of PJP in our study. It is tempting to speculate that the apparent differences that we observed between 
PJP+AAV+ and controls were reflecting more aggressive initial AAV rather than representing risk factors for 
late onset PJP. 
There are a number of limitations to our study. First, this is a single centre, retrospective study with inherent 
potential for selection & recall bias and it is relatively small sample size group. Second, BVAS scores are not 
available for the patients included in this study to directly compare the contribution of disease severity to PJP 
infections. Thirdly, we were unable to assess the impact of immunosuppression agents used as maintenance 
treatment in both groups and also to assess the impact of combination and consecutive use of different agents. 
A limited number of risk factors were considered in this study and we cannot rule out the presence of other 
potential confounding factors e.g. ethnicity, serum albumin, or severe malnutrition. 
In conclusion, PJP can occur beyond the early induction period in AAV, especially in context of escalating 
immunosuppression. Extended PJP prophylaxis might be of value when augmented immunosuppression is 
considered, especially in the presence of lymphopenia. Previously recognized risk factors that were proved to be 
useful predictors for PJP occurring early in the course of AAV, were not predictor of late onset PJP. Registry 
data or multi-centre observational studies are needed to stratify infection risks and prophylaxis strategies in 
AAV.    
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Table 1: Characteristics of vasculitis patients who developed PJP infection 
 
Age, median (IQR) 66.5 (52.5-73.7) 
Sex (Female/Male) 8/8 
Diagnosis 
GPA/MPA/EGPA 
 
12/2/2 
Escalation of immunosuppression  
(see table 3 for more details) 
6/16 
Daily prednisolone dose (mg) at time of PJP diagnosis, median (IQR) 10 (8.1-18.7) 
Disease duration at event, months, median (IQR) 8 (7-127.5) 
Test to confirm diagnosis & Method used to obtain sputum sample 
DNA PCR 
Induced sputum 
BAL 
 
16 
11 
5 
Lymphocytes count*x109 median (IQR) 0.35 (0.2-0.7) 
Neutrophils count*x109 median (IQR) 6.8 (5.7-9) 
Serum Creatinine µmol/L, median (IQR) 111 (84-180) 
Hospital stay, days (IQR) 11 (6-19.2) 
 
GPA=granulomatosis with polyangiitis, MPA=microscopic polyangiitis, EGPA=eosinophilic 
granulomatosis with polyangiitis, BAL: Bronchoalveolar Lavage. 
 
*Lymphocytes or neutrophils count within 30 days from the onset of PJP. Categorical variables values 
are number (%) and continuous variables are median (IQR).                      
Table 2: Details of Cases with confirmed PJP    Age at 
time of 
PJP 
infection 
(Years) 
Sex GPA/MPA/ 
EGPA 
ANCA type Organ 
involvement at 
presentation 
Induction 
Immunosuppression 
PJP prophylaxis 
at induction 
Maintenance 
Immunosuppression 
Prior to PJP infection 
Any relapses 
Within 3 months?  
Type of Escalation or 
change of 
immunosuppression  
Duration between: 
I) Vasculitis diagnosis & 
PJP infection 
II) Immunosuppression 
escalation  & PJP 
infection  
  
 
  
Case 1 74 F GPA Anti-PR3 Kidneys, Peripheral Nervous System Oral CYC Prednisolone  Yes AZA Yes  - Minor AZA to MMF I) 210 days  II) 35 days  
 
Case 2 54 M EGPA ANCA-Negative Lungs Oral CYC Prednisolone Yes AZA, MTX No  I) 210 days  
Case 3 64 F GPA Anti-PR3 Lungs Oral CYC Prednisolone Yes AZA No  I) 270 days  Case 4 52 M GPA Anti-PR3 ENT, Scleritis, Arthritis  Oral CYC Prednisolone Unable to confirm  MTX, AZA MMF No    I) 5640 days  Case 5 77 F GPA Anti-PR3 Kidneys  Oral CYC Prednisolone Yes AZA No  I) 240 days  Case 6 47 F GPA Anti-PR3 Kidneys IV CYC Prednisolone Unable to confirm AZA, MMF No  I) 9120 days  Case 7 75 F MPA Anti-MPO Kidneys Oral CYC Prednisolone Yes AZA No  I) 105 days  Case 8 73 M GPA Anti-PR3 Lungs, Kidneys Oral CYC Prednisolone Yes AZA No  I) 180 days  Case 9 49 M GPA Anti-PR3 Kidneys Oral CYC Prednisolone Yes AZA, Yes  - Minor AZA to MMF I) 4080 days  II) 85 days  
 
Case 10 67 F GPA Anti-PR3 Lungs Oral CYC Prednisolone Yes AZA, MMF No  I) 3060 days  Case 11 66 M GPA Anti-PR3 Joints, Kidneys Oral CYC Prednisolone Yes AZA, MMF No  I) 330 days  Case 12 54 F GPA Anti-PR3 ENT, Kidneys  Oral CYC Prednisolone Yes AZA Yes  - Minor AZA to MTX then adding Rituximab� I) 240 days  II) 68 days   Case 13 71 M GPA, Anti-GBM Anti-PR3, Anti GBM Lungs, Kidneys Oral CYC Prednisolone Yes AZA No  I) 135 days  Case 14 70 M MPA Anti-MPO Kidneys Oral CYC Prednisolone Yes AZA, MTX Yes  - Minor MTX to MMF I) 4650 days  II) 32 days  Case 15  37 F EGPA ANCA-Negative GI Oral CYC Prednisolone Yes AZA Yes  - Minor AZA to MMF I) 210 days II) 36 days  Case 16 76 M MPA Anti-MPO Kidneys Oral CYC Prednisolone Yes AZA Yes-   Major AZA to Rituximab  I) 210 days  II) 34 days   GPA: Granulomatosis with Polyangiitis, EGPA: Eosinophilic Granulomatosis with Polyangiitis, MPA: Microscopic Polyangiitis, CYC: Cyclophosphamide, AZA: Azathioprine, MMF: Mycophenolate Mofetil,  MTX: Methotrexate.  
�Use of Rituximab in this case for minor relapse though is inconsistent with our local protocol but given severity of disease at presentation and multiple symptoms reported the treating clinician opted to   treat as major Relapse   
Table 3: Participant characteristics-cases and controls 
 PJP (n=16) Control  (n=141) Significance 
Age, median (IQR) 66.5 (52.5-73.7) 62.6 (51.7-71.1) 0.96 
Sex (Female/Male) 8/8 57/84 0.46 
Organ involvement  at presentation & later during 
follow up period  (%) 
Renal 
Lung 
ENT 
 
14 (87) 
10 (62) 
8  (50) 
 
79 (56) 
63 (45) 
51 (36) 
 
0.01 
0.18 
0.29 
PR3/MPO/negative  11/3/2 63/63/15 0.07 
Creatinine at presentation µmol/L, median (IQR) 150 (79-533) 100 (74-225) 0.26 
Lymphocytes x109, median (IQR) 0.4 (0.1-0.8) 0.6 (0.4-1.1) 0.04 
Neutropenia during induction therapy  (%) 4 (27) 19(14) 0.4 
Induction therapy (%) 
Oral Cyclophosphamide 
Pulse Cyclophosphamide 
Rituximab 
Mycophenolate mofetil 
Methotrexate 
Azathioprine 
Steroid only 
 
 
15(94) 
1 (6) 
0 
0 
0 
0 
0 
 
93(66) 
5 (3.5) 
10 (7) 
19 (13.5) 
6 (4.3) 
1 (0.7) 
7 (5) 
 
0.02 
0.5 
0.6 
0.2 
1.0 
1.0 
1.0 
PJP prophylaxis at induction (%) 14 (87.5) 108 (76.5) 0.7 
Relapse, number of patients with at least one 
relapse episode * 
Major relapse 
Minor relapse 
Time from diagnosis to relapse in months (IQR) 
 
Relapse treatment 
Rituximab 
Mycophenolate mofetil 
Methotrexate 
Azathioprine 
Cyclophosphamide 
Steroid increment only 
 
10 (62.5) 
 
3 (30) 
7 (70) 
12 (6-50) 
 
 
4 (40) 
4 (40) 
3 (30) 
1 (10) 
0 
1 (10) 
 
55 (39) 
 
 27 (49) 
28 (51) 
11 (5-18) 
 
 
23 (42) 
9 (16.4) 
9 (16.4) 
3 (5.5) 
4 (7) 
6 (11) 
0.1 
 
0.7** 
0.7 
0.4 
 
 
0.8 
0.2 
0.7 
1.0 
1.0 
1 
 
Mortality 2 (13) 13 (14) 0.6 
 
Categorical variables values are number (%) and continuous variables are median (IQR).  
*Episodes of relapse are counted from diagnosis of Vasculitis to onset of PJP infection  
**Chi square used to test differences in the frequencies of major and minor relapses between PJP and control groups.    
